Market news

In September 2026, REGENXBIO and the University of Pennsylvania settled their patent infringement litigation with Sarepta Therapeutics and Catalent over ELEVIDYS, with Sarepta agreeing to pay US$39.0 million and receiving broad freedom to operate on AAVrh74-based gene therapies under specified patents. The settlement not only closes costly legal disputes but also removes a significant patent overhang on ELEVIDYS and related AAVrh74 programs, potentially clarifying Sarepta’s long-term gene...

Sarepta Therapeutics (NASDAQ:SRPT) outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic dystrophy type 1, or DM1, during a Morgan Stanley Global Healthcare Conference fireside chat. Chie

Novartis stock sinks 13% after del-desiran phase 3 trial failed primary endpoints, sparking biotech selloff.

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CAMBRIDGE, Mass., August 31, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Sept. 14, at 8:30 a.m. ET.

Sarepta (SRPT) is rated hold: ELEVIDYS uptake faces friction and execution risk despite better profitability. Read here for a detailed investment analysis.

Investors are now awaiting extra data from Sarepta’s mid-stage studies in two muscle diseases, facioscapulohumeral muscular dystrophy and myotonic dystrophy.

Sarepta Therapeutics stock has seen a steep share price decline over the past few years, yet on current market multiples it still screens as expensive rather than clearly cheap. With the valuation checks giving a mixed signal, investors are left weighing recent performance against the current pricing. The share price decline of around 84.7% over the past 3 years points to a company where expectations have reset sharply and long term holders have faced heavy losses. Future progress in Sarepta...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics (NASDAQ:SRPT) reported second-quarter 2026 total revenue of $401 million, down 34% from a year earlier, as lower ELEVIDYS sales weighed on results. The company nevertheless posted GAAP operating income of $13 million and non-GAAP operating income of $86 million, while increasing

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Sarepta stock rises after Q2 earnings beat amid Elevidys label impact and revenue drop. Read more here.

Sarepta Therapeutics: Q2 Earnings Snapshot

CAMBRIDGE, Mass., August 05, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2026.

Sarepta Therapeutics (SRPT) has drawn fresh attention after filing a US$39.7 million shelf registration tied to an employee stock ownership plan, alongside appointing Michael Severino, M.D., as its new Chief Executive Officer. See our latest analysis for Sarepta Therapeutics. The CEO transition and fresh equity capacity come after a period where Sarepta Therapeutics’ share price has fallen 30.9% over the past three months and 30.3% year to date, while the 3 year total shareholder return is...

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CAMBRIDGE, Mass., July 29, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously approved by its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as amended, as a material inducement to employment to Michael Severino, M.D. as Chief Executive Officer of Sarepta. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

July 27 () - Sarepta Therapeutics said on Monday it appointed former Tessera Therapeutics CEO ‌Michael Severino its chief executive, effective ‌July 28. The longtime AbbVie executive, will succeed Doug ​Ingram.

Morgan Stanley said it remains cautious in the near term because of continued challenges in the company's Duchenne muscular dystrophy business.

CAMBRIDGE, Mass., July 27, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition.

Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company facing emerging competition and declining sales for its prized gene therapy Elevidys.

Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.

CAMBRIDGE, Mass., July 22, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, Aug. 5, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss these results.

FDA sNDA Acceptance Puts Sarepta Therapeutics Stock in Focus Sarepta Therapeutics (SRPT) recently reported that the FDA accepted supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53, seeking conversion from accelerated to traditional approvals in Duchenne muscular dystrophy. This regulatory step, backed by Phase 3 ESSENCE data and real world evidence on efficacy trends and safety, gives investors a new reference point for evaluating Sarepta Therapeutics stock and its Duchenne...

In June 2026, Sarepta Therapeutics announced that the FDA accepted supplemental New Drug Applications to convert accelerated approvals for its Duchenne muscular dystrophy exon-skipping therapies AMONDYS 45 and VYONDYS 53 to traditional approvals, with a PDUFA action date set for February 28, 2027. This move, backed by the ESSENCE confirmatory study and extensive real-world evidence across more than 1,800 treated patients, could be important for reinforcing the long-term regulatory footing of...

Your hard-earned money would be better spent elsewhere.